Efficacy of low-dose D(2)/D(3) partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study

OBJECTIVE: Some lines of evidence show that D(2)/D(3) receptor partial agonist pramipexole may be effective in the treatment of extrapyramidal symptoms (EPS) and psychiatric symptoms of schizophrenia. Therefore, we analyzed whether a low dose of pramipexole (0.375–0.75 mg/day) has efficacy on EPS an...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Jia Jun, Wang, Li Hua, Zhu, Hao, Xu, Wen Rong, Wei, Yu Mei, Wang, Zhi Yang, Yu, Wen Juan, Li, Hua Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689661/
https://www.ncbi.nlm.nih.gov/pubmed/31496702
http://dx.doi.org/10.2147/NDT.S205933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689661/
https://www.ncbi.nlm.nih.gov/pubmed/31496702
http://dx.doi.org/10.2147/NDT.S205933

Ejemplares similares